China-based cancer diagnostics technology developer Gene+ Technology has secured RMB200m ($28m) in a series B round featuring genome sequencing technology provider BGI and IT services firm UEC, China Money Network has reported.
Private equity firm Co-Stone Asset Management led the round, which included Volcanics Venture, Green Pine Capital Partners and Desun Asset.
Gene+ has developed a gene-testing platform that detects signs of cancer at an early stage and which can be used to monitor for signs of recurrence. The technology also has applications in precision medicine and the tracking of efficacy of treatments.
BGI led a $30m series A round for Gene+ in 2016, investing alongside Green Pine Capital Partners and Shanghai Huoshanshi Capital, before adding $7.4m in funding in January this year.
